Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Study

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 66, Iss. 12, 2014-12 ,pp. : 3255-3264

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tofacitinib With Methotrexate in Third‐Line Treatment of Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Trial

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 4, 2015-04 ,pp. : 475-483

John Wiley & Sons Inc

Access to resources Recommend Favorite

Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week‐112 Efficacy and Safety Results of the Open‐Label Long‐Term Extension of a Phase III, Double‐Blind, Randomized, Placebo‐Controlled Trial

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 12, 2015-12 ,pp. : 1627-1636

John Wiley & Sons Inc

Access to resources Recommend Favorite

Etanercept and methotrexate for the treatment of rheumatoid arthritis

By Miyasaka Nobuyuki  

Therapy, Vol. 3, Iss. 3, 2006-05 ,pp. : 365-373

Future Medicine

Access to resources Recommend Favorite

Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial

By Fleischmann R. M.   Cohen S. B.   Moreland L. W.   Schiff M.   Mease P. J.   Smith D. B.   Keenan G.   Kremer J. M.    

Current Medical Research and Opinion, Vol. 21, Iss. 8, 2005-08 ,pp. : 1181-1190

Informa Healthcare

Access to resources Recommend Favorite